natgillin/translations-raw huggingface dataset:
Administration of emtricitabine/tenofovir disoproxil with food resulted in a delay of approximately three quarters of an hour in reaching maximum tenofovir concentrations and increases in tenofovir AUC and Cmax of approximately 35% and 15%, respectively, when administered with a high fat or light meal, compared to administration in the fasted state.
Jemanje emtricitabina / dizoproksiltenofovirata s hrano se je odražalo v približno tričetrturni zakasnitvi pri doseganju maksimalne koncentracije tenofovirja ter povečanju AUC tenofovirja za približno 35% in Cmax za približno 15% pri jemanju ob z maščobami bogatem ali lažjem obroku, v primerjavi z jemanjem na tešče.
Administration of Esbriet with food results in a large reduction in Cmax (by 50%) and a smaller effect on AUC, compared to the fasted state.
Z jemanjem zdravila Esbriet skupaj s hrano se zelo zmanjša vrednost Cmax (za 50 %), učinek na vrednost AUC pa je manjši, kot če je zaužit na prazen želodec.
Administration of eslicarbazepine acetate 1,200 mg once daily to female subjects using a combined oral contraceptive showed an average decrease of 37% and 42% in systemic exposure to levonorgestrel and ethinyloestradiol, respectively, most likely caused by an induction of CYP3A4.
Pri uporabi 1.200 mg eslikarbazepinacetata enkrat na dan pri ženskah, ki uporabljajo kombinirane peroralne kontraceptive, je prišlo do povprečnega 37-odstotnega zmanjšanja sistemske izpostavljenosti levonorgestrelu in 42-odstotnega zmanjšanja sistemske izpostavljenosti etinilestradiolu, ki je najverjetneje bilo posledica indukcije CYP3A4.
Administration of exenatide has been shown to reduce food intake, due to decreased appetite and increased satiety.
Ugotovili so, da jemanje eksenatida zaradi zmanjšanega apetita in povečanega občutka sitosti zmanjša vnos hrane.
Administration of febuxostat (80 mg or 120 mg once daily) with warfarin had no effect on the pharmacokinetics of warfarin in healthy subjects.
Dajanje febuksostata (80 mg ali 120 mg enkrat na dan) z varfarinom ni imelo učinka a farmakokinetiko varfarina pri zdravih osebah.
administration of fosamprenavir/ritonavir with paritaprevir/ritonavir/ ombitasvir +/- dasabuvir is likely to lead to increased plasma exposures of paritaprevir due to CYP3A4 enzyme inhibition and higher ritonavir dose.
+/-/ dasabuvirjem verjetno poveča izpostavljenost paritaprevirju v plazmi zaradi zavrtja encima CYP3A4 in večjega odmerka ritonavirja.
administration of fosamprenavir/ritonavir with paritaprevir/ritonavir/ ombitasvir+/-dasabuvir is likely to lead to increased plasma exposures of paritaprevir due to CYP3A4 enzyme inhibition and higher ritonavir dose.
+/- dasabuvirjem verjetno poveča izpostavljenost paritaprevirju v plazmi zaradi zavrtja encima CYP3A4 in večjega odmerka ritonavirja.
Administration of gefitinib once daily results in 2- to 8-fold accumulation, with steady-state exposures achieved after 7 to 10 doses.
Uporaba gefitiniba enkrat na dan povzroči od 2- do 8-kratno kopičenje; izpostavljenost v stanju dinamičnega ravnovesja je dosežena po 7 do 10 odmerkih.
Administration of Humira without methotrexate resulted in increased formation of antibodies, increased clearance and reduced efficacy of adalimumab (see section 5.1).
Uporaba zdravila Humira brez metotreksata je zvečala nastajanje protiteles, zvečala očistek in zmanjšala učinkovitost adalimumaba (glejte poglavje 5.1).
Administration of Ibandronic acid Accord 3 mg solution for injection in pre-filled syringe:
Dajanje zdravila Ibandronska kislina Accord 3 mg raztopina za injiciranje v napolnjeni injekcijski brizgi:
Administration of IMBRUVICA with inducers of CYP3A4 can decrease ibrutinib plasma concentrations.
Sočasna uporaba zdravila IMBRUVICA z induktorji CYP3A4 lahko zmanjša koncentracijo ibrutiniba v plazmi.
Administration of Inflectra should be discontinued if a patient develops a new serious infection or sepsis, and appropriate antimicrobial or antifungal therapy should be initiated until the infection is controlled.
Uporabo zdravila Inflectra prekinite, če se pri bolniku pojavi nova resna okužba ali sepsa, in mu uvedite ustrezno protimikrobno ali protiglivično terapijo, dokler ne bo okužba obvladana.
Administration of insulin lispro to children below 12 years of age should be considered only in case of an expected benefit when compared to regular insulin.
O dajanju insulina lispro otrokom, mlajšim od 12 let, naj se razmišlja samo v primeru pričakovane koristi v primerjavi z navadnim insulinom.
administration of Invirase and parenteral midazolam.
uporabi zdravila Invirase s
Administration of iodinated contrast agent
Aplikacija jodiranega kontrastnega sredstva
Administration of Ipreziv for up to 5 days in subjects with mild (Child-Pugh A) or moderate (Child- Pugh B) hepatic impairment resulted in slight increase in azilsartan exposure (AUC increased by 1.3 to 1.6 fold, see section 4.2).
Dajanje zdravila Ipreziv bolnikom z blago (Child-Pugh A) ali zmerno (Child-Pugh B) jetrno okvaro v trajanju 5 dni, je pokazalo majhno povečanje izpostavljenosti azilsartanu (AUC se je povečala za 1,3 do 1,6-krat; glejte poglavje 4.2).
Administration of isavuconazonium sulfate to rats at a dose of 90 mg/kg/day (2.3-fold the human maintenance dose [200 mg] based on mg/m2/day) during pregnancy through the weaning period showed an increased perinatal mortality of the pups.
Pri dajanju 90 mg/kg/dan izavukonazonijevega sulfata (2,3-kratnik vzdrţevalnega odmerka pri človeku [200 mg] na podlagi mg/m2/dan) med brejostjo do časa odstavitve mladiča od dojenja se je pokazala povečana perinatalna umrljivost mladičev.
Administration of ivacaftor may increase systemic exposure of medicinal products that are sensitive substrates of CYP3A and/or P-gp, which may increase or prolong their therapeutic effect and adverse reactions.
Uporaba ivakaftorja lahko zveča sistemsko izpostavljenost zdravilom, ki so občutljivi substrati CYP3A in/ali P- gp, kar lahko zveča ali podaljša njihov terapevtski učinek in neželene učinke.
Administration of lamivudine at very high dose levels in acute animal studies did not result in any organ toxicity.
Dajanje zelo velikih odmerkov lamivudina v akutnih študijah na živalih ni imelo toksičnega vpliva na noben organ.
Administration of lamivudine in animal toxicity studies at high doses was not associated with any major organ toxicity.
V študijah toksičnosti na živalih dajanje velikih odmerkov lamivudina ni bilo povezano s toksičnostjo za kakšen pomemben organ.
Administration of live or live-attenuated vaccines in patients immunocompromised by chemotherapeutic agents including doxorubicin may result in serious or fatal infections.
Uporaba živih ali živih oslabljenih cepiv pri bolnikih, imunsko oslabljenih zaradi kemoterapevtikov, vključno z doksorubicinom, lahko povzroči resne ali smrtne okužbe.
Administration of live or live-attenuated vaccines in patients immunocompromised by chemotherapeutic medicinal products including ONIVYDE may result in serious or fatal infections; therefore vaccination with a live vaccine should be avoided.
Dajanje živih ali atenuiranih cepiv bolnikom z oslabljenim imunskim sistemom zaradi kemoterapevtskih zdravil, vključno z zdravilom ONIVYDE, lahko povzroči resne ali smrtne okužbe, zato se je treba cepljenju z živimi cepivi izogibati.
Administration of live vaccines to infants exposed to adalimumab in utero is not recommended for 5 months following the mother’s last adalimumab injection during pregnancy.
Uporaba živih cepiv pri dojenčkih, ki so bili izpostavljeni adalimumabu in utero, ni priporočljiva 5 mesecev po zadnji injekciji adalimumaba, ki jo je mati prejela med nosečnostjo.
Administration of live vaccines to infants exposed to adalimumab in utero is not recommended for 5 months following the mother’s last adalimumab injection during pregnancy.
Uporaba živih cepiv pri dojenčkih, ki so bili izpostavljeni adalimumabu in utero, ni priporočljiva še 5 mesecev po materini zadnji injekciji adalimumaba med nosečnostjo.
Administration of live vaccines to infants exposed to certolizumab pegol in utero is not recommended for a minimum of 5 months following the mother’s last Cimzia administration during pregnancy (see section 4.4).
Uporaba živih cepiv pri dojenčkih, ki so bili izpostavljeni certolizumabu in utero, ni priporočljiva še vsaj 5 mesecev po materini zadnji uporabi certolizumaba med nosečnostjo (glejte poglavje 4.4).
Administration of live vaccines to infants exposed to golimumab in utero is not recommended for 6 months following the mother’s last golimumab injection during pregnancy (see sections 4.4 and 4.5).
Dajanje živih cepiv dojenčkom, ki so bili izpostavljeni golimumabu in utero, ni priporočljivo še 6 mesecev po materini zadnji injekciji golimumaba v času nosečnosti (glejte poglavji 4.4 in 4.5).
Administration of live vaccines to infants for 16 weeks after the mother’s last dose of Benepali is generally not recommended.
Uporaba živih cepiv v prvih 16 tednih po tem, ko so matere dojenčkov prejele zadnji odmerek zdravila Benepali, pri dojenčkih običajno ni priporočljiva.
Administration of live vaccines to infants for 16 weeks after the mother’s last dose of Enbrel is generally not recommended.
Uporaba živih cepiv v prvih 16 tednih po tem, ko so matere dojenčkov prejele zadnji odmerek zdravila Enbrel, pri dojenčkih običajno ni priporočljiva.
Administration of Lymphoseek and conduct of the procedure
Injiciranje zdravila Lymphoseek in izvajanje postopka
Administration of Marixino is not recommended in patients with severe hepatic impairment.
Dajanje zdravila Marixino bolnikom s hudo jetrno okvaro ni priporočljivo.
Administration of Memantine Accord is not recommended in patients with severe hepatic impairment.
Dajanje zdravila Memantin Accord bolnikom s hudo jetrno okvaro ni priporočeno.
Administration of Memantine Merz is not recommended in patients with severe hepatic impairment.
Dajanje zdravila Memantine Merz bolnikom s hudo jetrno okvaro ni priporočeno.
Administration of miglustat to male and female Sprague-Dawley rats by oral gavage for 2 years at dose levels of 30, 60 and 180 mg/kg/day resulted in an increased incidence of testicular interstitial cell (Leydig cell) hyperplasia and adenomas in male rats at all dose levels.
Dajanje miglustata samcem in samicam podgan Sprague-Dawley po sondi 2 leti v odmerkih 30, 60 in 180 mg/kg/dan je povzročilo povišano incidenco hiperplazije testikularnih intersticijskih (Leydigovih) celic in adenomov pri samcih pri vseh odmerkih.
Administration of Mimpara with food results in an approximate 50 – 80% increase in cinacalcet bioavailability.
Zaužitje zdravila Mimpara s hrano poveča biološko uporabnost cinakalceta za približno 50-80 %.
Administration of multiple doses of rifampicin decreased sirolimus whole blood concentrations following a single 10 mg dose of Rapamune oral solution.
Dajanje večkratnih odmerkov rifampicina zniža koncentracije sirolimusa v polni krvi po enkratnem 10 mg odmerku peroralne raztopine zdravila Rapamune.
Administration of nintedanib was also associated with elevations of bilirubin.
Dajanje nintedaniba je bilo povezano tudi z zvišanjem ravni bilirubina.
Administration of nintedanib was associated with an elevation of liver enzymes (ALT, AST, ALKP, gamma-glutamyltransferase) or bilirubin, with a potentially higher risk for female patients.
Dajanje nintedaniba je bilo povezano s povečano ravnijo jetrnih encimov (ALT, AST, ALKP in gama-glutamiltransferaze) ali bilirubina, z možnim večjim tveganjem za bolnice.
Administration of nintedanib was associated with elevations of liver enzymes (ALT, AST, alkaline phosphatase (ALKP), gamma-glutamyl-transferase (GGT)) with a potentially higher risk for female patients.
Dajanje nintedaniba je bilo povezano z zvišano ravnjo jetrnih encimov (ALT, AST in alkalne fosfataze (ALKP), gama-glutamil-transferaze (GGT) z možnim večjim tveganjem za bolnice.
Administration of oral cyclosporine A (15 mg/kg), an inhibitor of transporters ABCB1 (P-gp) and ABCC1 (MRP-1) as well as the metabolising enzyme CYP3A4, within 4 hours of oral topotecan increased the dose normalised AUC0-24h of topotecan lactone and total topotecan approximately 2.0- and 2.5-fold, respectively (see section 4.5).
Peroralno uporabljeni ciklosporin A (15 mg/kg), zaviralec transportnih beljakovin ABCB1 (P-gp) in ABCC1 (MRP-1) ter presnovnega encima CYP3A4, je v 4 urah po peroralnem topotekanu povečal za odmerek normalizirano AUC0–24h topotekanovega laktona za približno 2,0-krat in celotnega topotekana za približno 2,5-krat (glejte poglavje 4.5).
Administration of Orkambi may decrease systemic exposure of medicinal products which are substrates of CYP3A, thereby decreasing their therapeutic effect.
Uporaba zdravila Orkambi utegne zmanjšati sistemsko izpostavljenost zdravilom, ki so substrati CYP3A, in s tem njihov terapevtski učinek.
Administration of pazopanib to patients with mild or moderate hepatic impairment should be undertaken with caution and close monitoring.
Pri bolnikih z blago do zmerno okvaro jeter je treba pazopanib uporabiti previdno in ob natančnem spremljanju.
Administration of pazopanib with a high fat or low fat meal results in an approximately 2-fold increase in AUC and Cmax.
Pri uporabi pazopaniba skupaj z obrokom z veliko ali majhno vsebnostjo maščob sta se vrednosti AUC in Cmax pazopaniba povečali za približno 2-krat.
Administration of pemetrexed to pregnant mice resulted in decreased foetal viability, decreased foetal weight, incomplete ossification of some skeletal structures, and cleft palate
Dajanje pemetrekseda brejim mišim je povzročilo zmanjšano preživetje plodov, zmanjšano maso plodov, nepopolno okostenevanje določenih struktur okostja in shize neba.
Administration of pomalidomide in smokers, with smoking tobacco known to induce the CYP1A2 isoform, had no clinically relevant effect on exposure to pomalidomide compared to that exposure to pomalidomide observed in non-smokers.
Uporaba pomalidomida pri kadilcih, pri čemer je znano, da kajenje tobaka inducira izoobliko CYP1A2, ni klinično pomembno vplivalo na izpostavljenost pomalidomidu v primerjavi s to izpostavljenostjo pri nekadilcih (glejte poglavje 4.2).
Administration of PREZISTA 800 mg once daily with low dose ritonavir in treatment-naïve adolescents 12 to 17 years weighing at least 40 kg leads to darunavir exposures within the therapeutic range as established in adults receiving the same dosing regimen.
Jemanje 800 mg zdravila PREZISTA enkrat na dan skupaj z majhnim odmerkom ritonavirja pri mladostnikih, starih 12 do 17 let in s telesno maso najmanj 40 kg, ki še nimajo izkušenj z zdravljenjem, vodi v izpostavljenost darunavirju v terapevtskem obsegu, kot je ugotovljen pri odraslih pri enakem odmerjanju.
Administration of protein-rich foods increases the bioavailability of propranolol by about 50% with no change in time to peak concentration.
Dajanje hrane, bogate z beljakovinami, poveča biološko uporabnost propranolola za približno 50 % brez spremembe v času do najvišje koncentracije.
Administration of rapid-acting insulin is recommended in situations with severe hyperglycaemia.
V primerih hude hiperglikemije se priporoča apliciranje hitrodelujočega insulina.
Administration of regorafenib (160 mg for 14 days) prior to administration of a single dose of rosuvastatin (5 mg), a BCRP substrate, resulted in a 3.8-fold increase in mean exposure (AUC) of rosuvastatin and a 4.6-fold increase in Cmax.
Uporaba regorafeniba (160 mg 14 dni) pred administracijo enkratnega odmerka rosuvastatina (5 mg), substrata BCRP, povzroči 3,8-kratno povečanje povprečne izpostavljenosti (AUC) rosuvastatina in 4,6-kratno povečanje Cmax.
Administration of Remsima should be discontinued if a patient develops a new serious infection or sepsis, and appropriate antimicrobial or antifungal therapy should be initiated until the infection is controlled.
Uporabo zdravila Remsima prekinite, če se pri bolniku pojavi nova resna okužba ali sepsa, in mu uvedite ustrezno protimikrobno ali protiglivično terapijo, dokler ne bo okužba obvladana.
Administration of REYATAZ and infant formula using an infant bottle is not recommended because the full dose may not be delivered.
Dajanje zdravila REYATAZ in začetne formule za dojenčke s pomočjo stekleničke za hranjenje dojenčkov ni priporočljivo, saj otrok morda ne bo zaužil celotnega odmerka.
Administration of rifampicin (600 mg for 9 days), a strong CYP3A4 inducer, with a single dose of regorafenib (160 mg on day 7) resulted in a reduction in AUC of regorafenib of approximately 50%, a 3- to 4-fold increase in mean exposure of the active metabolite M-5, and no change in exposure of active metabolite M-2.
Uporaba rifampicina (600 mg 9 dni), močnega induktorja CYP3A4, z enkratnim odmerkom regorafeniba (160 mg sedmi dan), je povzročila zmanjšanje AUC regorafeniba za približno 50 %, kar je 3- do 4-kratno povečanje povprečne izpostavljenosti aktivnemu presnovku M-5; izpostavljenost aktivnemu presnovku M-2 se ni spremenila.
Administration of rivastigmine oral solution with food delays absorption (tmax) by 74 min and lowers Cmax by 43% and increases AUC by approximately 9%.
Jemanje peroralne raztopine rivastigmina skupaj s hrano upočasni absorpcijo (tmax) za 74 minut, zmanjša Cmax za 43 % ter poveča AUC za okrog 9 %.
Administration of rosiglitazone with food resulted in no change in overall exposure (AUC), although a small decrease in Cmax (approximately 20-28%) and a delay in tmax (approximately 1.75 h) were observed compared to dosing in the fasted state.
Uporaba rosiglitazona s hrano ni spremenila celotne izpostavljenosti (AUC), zabeležili pa so majhno zmanjšanje Cmax (približno 20–28 %) in zapoznitev tmax (približno 1,75 ure) v primerjavi z uporabo na tešče.
Administration of Rotarix to infants who have known or suspected immunodeficiency should be based on careful consideration of potential benefits and risks.
Uporaba cepiva Rotarix pri dojenčkih z znano imunsko pomanjkljivostjo ali sumom nanjo mora temeljiti na natančni oceni možnih koristi in tveganj.
Administration of salbutamol 30 minutes prior to EXUBERA in non-diabetic subjects with mild- moderate asthma resulted in an increase in insulin AUC and Cmax of between 25 and 51% compared to when EXUBERA was administered alone (see sections 4.2 and 4.5).
Uporaba salbutamola 30 minut pred EXUBERO je pri nediabetičnih preiskovancih z blago do zmerno astmo povzročila od 25 do 51 % povečanje AUC in Cmax v primerjavi z uporabo EXUBERE same (glejte poglavji 4.2 in 4.5).
Administration of Scintimun and conduct of the procedure
Dajanje zdravila Scintimun in izvajanje postopka
Administration of Simponi should be discontinued if a patient develops a new serious infection or sepsis, and appropriate antimicrobial or antifungal therapy should be initiated until the infection is controlled.
Če se pri bolniku pojavi nova resna okužba ali če dobi sepso, je treba uporabo zdravila Simponi prekiniti in uvesti ustrezno protimikrobno ali protiglivno terapijo, dokler ne bo okužba obvladana.
Administration of sunitinib with potent CYP3A4 inducers (e.g. dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital or herbal preparations containing St. John’s Wort/Hypericum perforatum) may decrease sunitinib concentrations.
Uporaba sunitiniba z močnimi induktorji CYP3A4 (npr. z deksametazonom, fenitoinom, karbamazepinom, rifampicinom, fenobarbitalom ali z rastlinskimi pripravki, ki vsebujejo šentjanževko / Hypericum perforatum) lahko zmanjša koncentracijo sunitiniba.
Administration of sunitinib with potent CYP3A4 inhibitors (e.g. ritonavir, itraconazole, erythromycin, clarithromycin, grapefruit juice) may increase sunitinib concentrations.
Uporaba sunitiniba z močnimi zaviralci CYP3A4 (npr. z ritonavirjem, itrakonazolom, eritromicinom, klaritromicinom, sokom grenivke) lahko zviša koncentracijo sunitiniba.
Administration of Tasigna 30 minutes or hours after food increased bioavailability of nilotinib by 29% or 15%, respectively (see sections 4.2, 4.4 and 4.5).
Aplikacija zdravila Tasigna 30 minut po obroku je zvečala biološko uporabnost nilotiniba za 29 %, 2 uri po obroku pa za 15% (glejte poglavja 4.2, 4.4 in 4.5).
Administration of tenofovir disoproxil fumarate with a high fat meal enhanced the oral bioavailability, with an increase in tenofovir AUC by approximately 40% and Cmax by approximately 14%.
Jemanje dizoproksiltenofovirijevega fumarata z z maščobami bogatim obrokom je povečalo peroralno biološko razpoložljivost s povečanjem AUC tenofovirja za približno 40% in Cmax za približno 14%.
Administration of the CYP3A4 inhibitor ketoconazole with Akynzeo increased the AUC of netupitant fold and Cmax 1.3 fold when compared to the administration of Akynzeo alone.
Dajanje zaviralca CYP3A4 ketokonazola z zdravilom Akynzeo je povečalo AUC netupitanta za 1,8-krat in Cmax za 1,3-krat v primerjavi z dajanjem samega zdravila Akynzeo.
Administration of the final diluted solution should be completed within six hours from the time that the Torisel is first added to sodium chloride 9 mg/ml (0.9%) solution for injection.
Končna razredčena raztopina mora biti do konca porabljena v šestih urah od takrat, ko zdravilo Torisel prvič dodate raztopini natrijevega klorida 9 mg/ml (0,9 %) za injiciranje.
Administration of the final diluted solution should be completed within six hours from the time that Torisel is first added to sodium chloride 9 mg/ml (0.9%) solution for injection.
Končna razredčena raztopina mora biti do konca porabljena v šestih urah od takrat, ko zdravilo Torisel prvič dodate raztopini natrijevega klorida 9 mg/ml (0,9 %) za injiciranje.
Administration of the fosamprenavir oral suspension formulation with a high fat meal (967 kcal, 67 grams fat, 33 grams protein, 58 grams carbohydrate) reduced plasma amprenavir AUC(0-) by 28% and Cmax by 46% and delayed Tmax by 0.72 hours.
Dajanje fosamprenavirja v obliki peroralne suspenzije skupaj z obrokom z veliko količino maščob (967 kcal, 67 g maščobe, 33 g beljakovin, 58 g ogljikovih hidratov) je plazemsko AUC amprenavirja (0-) zmanjšalo za 28 %, cmax za 48 % in tmax zakasnilo za 0,72 ure.
Administration of the fosamprenavir tablet formulation in the fed state (standardised high fat meal: 967 kcal, 67 grams fat, 33 grams protein, 58 grams carbohydrate) did not alter plasma amprenavir pharmacokinetics (Cmax, tmax or AUC0-) compared to the administration of this formulation in the fasted state.
Dajanje fosamprenavirja v obliki tablet po obroku (standardiziran obrok z veliko vsebnostjo maščob: 967 kcal, 67 g maščobe, 33 g beljakovin, 58 g ogljikovih hidratov) v primerjavi z dajanjem tablet na tešče ni spremenilo farmakokinetičnih lastnosti amprenavirja (Cmax, Tmax ali AUC0-).
Administration of the infusion solution
Dajanje raztopine za infundiranje
Administration of the medicinal product which caused displacement should be stopped in case of an infusion.
V primeru, da bolnik prejema takšno zdravilo v infuziji, je treba dajanje tega zdravila prekiniti.
Administration of the medicine radiolabelled with EndolucinBeta and conduct of the procedure EndolucinBeta must be used only in combination with another medicine (carrier medicine) which has been specifically developed and authorised for being combined with Lutetium (177Lu) chloride.
Dajanje zdravila, radioaktivno označenega z radionuklidnim predhodnikom EndolucinBeta, in izvedba postopka EndolucinBeta se lahko uporablja le skupaj z drugim zdravilom (nosilnim zdravilom), ki je bilo posebej razvito in odobreno za kombiniranje z lutecijevim (177Lu) kloridom.
Administration of the oral contraceptive 1 hour or 4 hours after lixisenatide did not affect AUC and t1/2 of ethinylestradiol and levonorgestrel, whereas Cmax of ethinylestradiol was decreased by 52% and 39%respectively and Cmax of levonorgestrel was decreased by 46% and 20%, respectively and median tmax was delayed by 1 to 3 hours.
Uporaba peroralnega kontraceptiva 1 uro ali 4 ure po liksisenatidu ni vplivala na AUC in t1/2 etinilestradiola in levonorgestrela, toda Cmax etinilestradiola se je zmanjšala za 52 % (1 ura) oziroma 39 % (4 ure), Cmax levonorgestrela pa za 46 % (1 ura) in 20 % (4 ure); mediani tmax se je podaljšal za 1 do 3 ure.